Skip to content
10-Q

Quarterly Report

Poseida Therapeutics, Inc.

0000950170-24-059551

← back to feed
Filed
May 14, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2024 · May 8, 2024 96.96M sh
Shares Diluted Q1 2024 · Mar 31, 2024 96.02M sh
Shares Diluted Q1 2024 · Mar 31, 2023 86.27M sh
Capex Q1 2024 · Mar 31, 2024 $130K
Capex Q1 2024 · Mar 31, 2023 $784K
Operating Cash Flow Q1 2024 · Mar 31, 2024 −$15.14M
Operating Cash Flow Q1 2024 · Mar 31, 2023 −$38.01M
Long Term Debt Q1 2024 · Mar 31, 2024 $58.69M
Long Term Debt Q1 2024 · Dec 31, 2023 $58.59M
Short Term Investments Q1 2024 · Mar 31, 2024 $145.35M
Short Term Investments Q1 2024 · Dec 31, 2023 $167.73M
Cash And Equivalents Q1 2024 · Mar 31, 2024 $53.3M
Cash And Equivalents Q1 2024 · Dec 31, 2023 $44.47M
Stockholders Equity Q1 2024 · Mar 31, 2024 $84.59M
Stockholders Equity Q1 2024 · Dec 31, 2023 $103.7M
Stockholders Equity Q1 2024 · Mar 31, 2023 $157.57M
Stockholders Equity Q1 2024 · Dec 31, 2022 $187.6M
Current Liabilities Q1 2024 · Mar 31, 2024 $84.76M
Current Liabilities Q1 2024 · Dec 31, 2023 $71.32M
Total Liabilities Q1 2024 · Mar 31, 2024 $177.99M
Total Liabilities Q1 2024 · Dec 31, 2023 $170.18M
Current Assets Q1 2024 · Mar 31, 2024 $216.73M
Current Assets Q1 2024 · Dec 31, 2023 $226.48M
Total Assets Q1 2024 · Mar 31, 2024 $262.58M
Total Assets Q1 2024 · Dec 31, 2023 $273.89M
Eps Diluted Q1 2024 · Mar 31, 2024 −$0.25
Eps Diluted Q1 2024 · Mar 31, 2023 −$0.45
Eps Basic Q1 2024 · Mar 31, 2024 −$0.25
Eps Basic Q1 2024 · Mar 31, 2023 −$0.45
Sga Expense Q1 2024 · Mar 31, 2024 $9.8M
Sga Expense Q1 2024 · Mar 31, 2023 $11.81M
Rd Expense Q1 2024 · Mar 31, 2024 $42.92M
Rd Expense Q1 2024 · Mar 31, 2023 $38.05M
Net Income Q1 2024 · Mar 31, 2024 −$24.27M
Net Income Q1 2024 · Mar 31, 2023 −$38.85M
Operating Income Q1 2024 · Mar 31, 2024 −$24.58M
Operating Income Q1 2024 · Mar 31, 2023 −$39.52M
Revenue Q1 2024 · Mar 31, 2024 $28.14M
Revenue Q1 2024 · Mar 31, 2023 $10.34M